Vis enkel innførsel

dc.contributor.authorCao, Maria Dungen_US
dc.contributor.authorGiskeødegård, Guro F.en_US
dc.contributor.authorBathen, Tone Frosten_US
dc.contributor.authorSitter, Beatheen_US
dc.contributor.authorBofin, Annaen_US
dc.contributor.authorLønning, Per Eysteinen_US
dc.contributor.authorLundgren, Steinaren_US
dc.contributor.authorGribbestad, Ingrid S.en_US
dc.date.accessioned2014-10-21T13:05:04Z
dc.date.available2014-10-21T13:05:04Z
dc.date.issued2012-01-25eng
dc.identifier.issn1471-2407
dc.identifier.urihttps://hdl.handle.net/1956/8659
dc.description.abstractBackground: Today’s clinical diagnostic tools are insufficient for giving accurate prognosis to breast cancer patients. The aim of our study was to examine the tumor metabolic changes in patients with locally advanced breast cancer caused by neoadjuvant chemotherapy (NAC), relating these changes to clinical treatment response and long-term survival. Methods: Patients (n = 89) participating in a randomized open-label multicenter study were allocated to receive either NAC as epirubicin or paclitaxel monotherapy. Biopsies were excised pre- and post-treatment, and analyzed by high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS). The metabolite profiles were examined by paired and unpaired multivariate methods and findings of important metabolites were confirmed by spectral integration of the metabolite peaks. Results: All patients had a significant metabolic response to NAC, and pre- and post-treatment spectra could be discriminated with 87.9%/68.9% classification accuracy by paired/unpaired partial least squares discriminant analysis (PLS-DA) (p < 0.001). Similar metabolic responses were observed for the two chemotherapeutic agents. The metabolic responses were related to patient outcome. Non-survivors (< 5 years) had increased tumor levels of lactate (p = 0.004) after treatment, while survivors (≥ 5 years) experienced a decrease in the levels of glycine (p = 0.047) and choline-containing compounds (p ≤ 0.013) and an increase in glucose (p = 0.002) levels. The metabolic responses were not related to clinical treatment response. Conclusions: The differences in tumor metabolic response to NAC were associated with breast cancer survival, but not to clinical response. Monitoring metabolic responses to NAC by HR MAS MRS may provide information about tumor biology related to individual prognosis.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0eng
dc.titlePrognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2013-08-23T09:27:32Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2012 Cao et al; licensee BioMed Central Ltd.
dc.rights.holderMaria D Cao et al.; licensee BioMed Central Ltd.
dc.source.articlenumber39
dc.identifier.doihttps://doi.org/10.1186/1471-2407-12-39
dc.identifier.cristin927651
dc.source.journalBMC Cancer
dc.source.4012


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY